Full Range Spectral Domain Anterior Segment OCT Scanner

全范围谱域眼前节 OCT 扫描仪

• 批准号: 7219581
• 负责人: Eric L. Buckland
• 金额: $ 15.5万
• 依托单位: BIOPTIGEN, INC.
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-07 至 2009-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7219581
• 关键词: Animal Experimentation; Animals; Anterior; Applied Research; Arts; Businesses; Class; Clinical; Collaborations; Complex; Computer software; Cornea; Depth; Diagnosis; Endothelium; Equus caballus; Excision; Exhibits; Glaucoma; Hand; Human; Image; Infant; Interferometry; Life; Marketing; Microscope; Morphologic artifacts; Mus; Noise; Operating System; Operative Surgical Procedures; Optical Coherence Tomography; Optics; Patients; Phase; Range; Rate; Research; Resolution; Retinal; Scanning; Signal Transduction; Small Animal Imaging Systems; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Specialist; Speed; Standards of Weights and Measures; Surface; System; Technology; Three-Dimensional Image; Three-Dimensional Imaging; Time; Tissues; Universities; base; corneal epithelium; design; improved; innovation; millimeter; new technology; novel strategies; pre-clinical research; prototype; size

DESCRIPTION (provided by applicant): In this Phase I Small Business Innovative Research application, Bioptigen Inc. proposes to prototype a portable, handheld cornea and anterior segment optical coherence tomography (CAS-OCT) scanner for use in clinical and applied research applications. OCT is a relatively new technology for ophthalmic imaging, which uses low-coherence interferometry to obtain cross-sectional images in living tissues with micron-scale resolution noninvasively. OCT systems based on the original time-domain interferometry technology have been successfully demonstrated for human retinal and anterior segment imaging at 830nm and 1300nm wavelengths, respectively, however the slower image acquisition rate and lower signal-to-noise ratio of the older technology places severe constraints on the range of subjects which can be successfully imaged. In order to immobilize patients for long acquisition times, retinal and anterior segment OCT imagers commercialized to date have been built into standard tabletop slit-lamp biomicroscope designs. The resulting systems are bulky and limit the range of potential subjects to cooperative humans who can sit upright and fixate well for several seconds. In the last few years, Fourier domain OCT (FDOCT) technology has emerged as a superior alternative to time-domain OCT, exhibiting improved image acquisition speed and robust system design. The increased image acquisition speed opens the possibility for the first time for ophthalmic OCT imaging with handheld probes, and the robust design potential of FDOCT enables the implementation of truly portable systems. Bioptigen, Inc., a startup company affiliated with Duke University, has marketed state-of-the- art retinal FDOCT systems operating at 830nm wavelength using both conventional and handheld delivery optics, and also markets a tabletop microscope-based 1300nm wavelength OCT system for small animal imaging and other pre-clinical research applications. However, due to a limitation intrinsic to FDOCT, both of these systems are limited in imaging depth to less than 4 millimeters, which is insufficient for full-depth anterior segment imaging. In this SBIR Phase I proposal, Bioptigen proposes to adapt their 1300nm OCT and handheld probe technology for high speed, handheld, full-depth anterior segment imaging which will make the benefits of ophthalmic OCT imaging available to a much wider class of subjects, including bedridden and infant human patients, as well as animals of all sizes (from mouse to horse) used in biomedical and veterinary research. In this Phase I Small Business Innovative Research application, Bioptigen Inc. proposes to prototype a portable, handheld cornea and anterior segment optical coherence tomography (CAS-OCT) scanner for use in clinical and applied research applications. This imaging system will be able to image the full depth of the anterior segment (> 6mm) by developing a novel approach to complex conjugate artifact removal.

描述（由申请人提供）：在此I期小型企业创新研究应用程序中，Bioptigen Inc.建议在临床和应用研究应用中使用便携式，手持角膜和前部光学相干断层扫描（CAS-OCT）扫描仪的原型。 OCT是一项针对眼科成像的相对较新的技术，它使用低稳态干涉仪在具有微米尺度分辨率的活组织中获得横截面图像。基于原始时间域干涉仪技术的OCT系统已在830nm和1300nm波长下成功地证明了人的视网膜和前部段成像，但是，较慢的图像采集率和较低的较旧技术的信噪比降低了，较旧技术对受试者范围的严重约束可以成功进行IMIMIMIMIMIP。为了固定患者长时间的收购时间，迄今已将其商业化的视网膜和前段OCT成像器已内置在标准的桌面狭缝灯泡生物显微镜设计中。最终的系统是笨重的，并将潜在受试者的范围限制为合作人，他们可以坐着直立并固定好几秒钟。在过去的几年中，傅立叶域OCT（FDOCT）技术已成为时间域OCT的优越替代品，表现出改善的图像采集速度和健壮的系统设计。提高的图像采集速度首次使用手持式探针进行眼科OCT成像的可能性，而FDOCT的强大设计潜力可以实现真正的便携式系统。 Bioptigen，Inc。是杜克大学（Duke University）隶属的一家初创公司，使用常规和手持式递送光学元件销售了830nm波长的最先进的视网膜FDOCT系统，并且还销售了基于桌面显微镜的1300NM波长OCT OCT系统，用于小型动物成像和其他临床前研究应用程序。但是，由于FDOCT固有的局限性，这两个系统在成像深度的限制至小于4毫米，这不足以全深度前段成像。在此SBIR I期建议中，Bioptigen提议将其1300nm的OCT和手持式探针技术改编成高速，手持式，全深度的前部成像，这将使您能够获得眼科的OCT成像的好处，可用于较宽的受试者，包括Bieldide和Birant Humanthimialional and All Shords Morse Morse Morse Morse Morse and Morse and Youls and Morse Morse sorse Morse and Youls and Youls and Youls and Youls and Youls and Youls）的好处。在这阶段，Bioptigen Inc.在此I阶段INSPARE INNOVATIVE研究应用程序中，建议在临床和应用研究应用程序中使用便携式，手持角膜和前部光学相干断层扫描（CAS-OCT）扫描仪。该成像系统将能够通过开发一种复杂的共轭伪影去除的新方法来对前段（> 6mm）的完整深度进行成像。